文献速递围术期管理与 ERAS急腹症与外科感染

左心室辅助装置治疗终末期心力衰竭:48例多中心报告

[Application of left ventricular assist device in the treatment of end-stage heart failure:a multi-center report of 48 cases].
PubMed 文献 · Zhonghua Wai Ke Za Zhi · 2025-01-01

国内8家心脏外科中心回顾性分析48例终末期心力衰竭患者行左心室辅助装置植入术,47例完成手术,围手术期死亡1例,随访期间死亡3例、过渡心脏移植1例、无主要装置故障。术后3个月左室舒张末期内径缩小、射血分数上升、6分钟步行距离延长,6个月时心功能恢复至NYHA Ⅰ~Ⅱ级。

要点

  • 终末期心衰NYHA Ⅳ级患者可考虑LVAD植入,本组47例手术完成。
  • 术后3个月心功能指标较术前显著改善,6个月恢复至NYHA Ⅰ~Ⅱ级。
  • LVAD可作为移植前过渡、恢复前过渡或永久性支持治疗。

核心结论

  • 初步研究显示左心室辅助装置治疗终末期心力衰竭效果较好,可作为移植前过渡、永久性支持或恢复前过渡治疗。

研究设计与样本

  • 回顾性病例系列研究,纳入2022年3月至2024年9月国内8家心脏外科中心连续收治的48例因终末期心力衰竭行LVAD植入术患者。
  • 男性42例、女性6例,年龄(59.1±12.3)岁(范围28~73岁),术前NYHA分级均为Ⅳ级,手术均由南京市第一医院心血管外科团队主导完成。

主要发现

  • 48例中47例顺利完成手术,围手术期死亡1例。
  • 47例获得随访,随访时间(12.2±0.8)个月(范围2~24个月),随访期间过渡心脏移植1例、死亡3例、无主要装置故障事件。
  • 术后3个月左室舒张末期内径较术前缩小[(69.1±8.3)mm比(77.3±8.3)mm,q=6.73,P<0.01]。
  • 术后3个月左室射血分数较术前上升[(29.6±8.0)%比(23.1±5.3)%,q=6.49,P<0.01]。
  • 术后3个月6分钟步行距离较术前延长[(382.0±12.8)m比(114.8±18.4)m,q=116.56,P<0.01]。

关键数值与推荐

  • 术中体外循环时间(122.4±21.6)min(范围101~200 min),循环阻断时间(70.1±18.3)min(范围58~150 min)。
  • 术后ICU住院时间(6.9±3.2)d(范围2~23 d),总住院时间(28.1±4.2)d(范围23~42 d)。
  • 出院时血泵流量(3.4±0.6)L/min(范围3.1~3.6 L/min),血泵转速(2 791.3±142.0)r/min(范围2 680~3 250 r/min)。
  • 术后6个月,42例获得随访患者心功能均恢复至NYHA分级Ⅰ~Ⅱ级。

临床怎么用

  • 对终末期心力衰竭NYHA Ⅳ级患者,LVAD可作为移植前过渡、恢复前过渡或永久性支持治疗的选择。
  • 术后需监测左室舒张末期内径、左室射血分数及6分钟步行距离等心功能指标变化。
  • 随访期间需关注装置故障事件及过渡心脏移植或死亡等结局。

局限性

  • 本研究为回顾性病例系列研究。
  • 样本量为48例,随访时间(12.2±0.8)个月(范围2~24个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the clinical efficacy of left ventricular assist device(LVAD) in the treatment of end-stage heart failure. Methods: This is a retrospective case series study. Data were retrospectively analyzed from 48 patients treated at eight domestic cardiac surgery centers in China between March 2022 and September 2024, who underwent LVAD implantation due to end-stage heart failure. All surgeries were led by the cardiovascular surgery team from Nanjing First Hospital. The study included 42 male and 6 female patients, aged (59.1±12.3) years (range:28 to 73 years). All patients had a preoperative New York Heart Association(NYHA) functional class of Ⅳ. General preoperative data, intraoperative extracorporeal circulation time, cross-clamp time, postoperative ICU stay, hospital stay, pump parameters at discharge, intraoperative and postoperative left ventricular end-diastolic diameter, left ventricular ejection fraction, and follow-up results post-discharge were collected. The generalized estimation equation was used to compare the difference of cardiac function indexes in patients with different follow-up time points. The Tukey's Honestly Significant Difference test was used for pairwise comparison within the group. Results: The surgery was successfully completed for 47 patients, and 1 perioperative death. The extracorporeal circulation time was (122.4±21.6) minutes (range: 101 to 200 minutes), the cross-clamp time was (70.1±18.3) minutes (range: 101 to 200 minutes), the postoperative ICU length of stay was (6.9±3.2) days (range: 2 to 23 days), and the hospital length of stay was (28.1±4.2) days (range: 23 to 42 days). At discharge, the blood bump flow rate was (3.4±0.6) L/min(range: 3.1 to 3.6 L/min), and speed was (2 791.3±142.0) r/min(range: 2 680 to 3 250 r/min). The follow-up period was (12.2±0.78) months (range:2 to 24 months) of 47 patients. One case underwent heart transplantation during the follow-up period, and 3 cases died, with no major device malfunction events. Three months post-surgery, the patients showed a significant reduction in left ventricular end-diastolic diameter compared to pre-surgery ((69.1±8.3) mm vs. (77.3±8.3) mm, q=6.73, P<0.01); the left ventricular ejection fraction significantly increased ((29.6±8.0)% vs. (23.2±5.8)%, q=6.49, P<0.01); and the 6-minute walk distance significantly improved ((382.0±12.8)metres vs. (114.8±18.4)metres, q=116.56, P<0.01). Six months postoperatively, all patients' cardiac function had recovered to NYHA class Ⅰor Ⅱ. Conclusions: Preliminary research findings indicate that left ventricular assist device therapy yields favorable outcomes in the treatment of end-stage heart failure. serving as a bridge to transplantation, recovery, or a destination therapy. 目的: 探讨左心室辅助装置在终末期心力衰竭治疗中的应用效果。 方法: 本研究为回顾性病例系列研究。回顾性分析2022年3月至2024年9月国内8家心脏外科中心连续收治的48例因终末期心力衰竭行左心室辅助装置植入术的患者资料。手术均由南京市第一医院心血管外科团队主导完成。男性42例,女性6例,年龄(59.1±12.3)岁(范围:28~73岁)。所有患者术前心功能纽约心脏病学会(NYHA)分级为Ⅳ级。收集患者术前一般资料、术中体外循环时间、循环阻断时间、术后ICU住院时间、总住院时间、出院时血泵参数、手术前后左心室舒张末期内径、左心室射血分数及术后随访结果。采用广义估计方程比较不同时间点患者心功能评估结果的差异,组内两两比较采用Tukey′s HSD检验。 结果: 48例患者中,47例患者顺利完成手术,围手术期死亡1例。术中体外循环时间(122.4±21.6)min(范围:101~200 min),循环阻断时间(70.1±18.3)min(范围:58~150 min),术后ICU住院时间(6.9±3.2)d(范围:2~23 d),总住院时间(28.1±4.2)d(范围:23~42 d)。出院时,血泵流量(3.4±0.6)L/min(范围:3.1~3.6 L/min),血泵转速(2 791.3±142.0)r/min(范围:2 680~3 250 r/min)。47例患者获得随访,随访时间(12.2±0.8)个月(范围:2~24个月),随访期间过渡心脏移植1例,死亡3例,无主要装置故障事件。术后3个月患者左室舒张末期内径较术前明显缩小[(69.1±8.3)mm比(77.3±8.3)mm,q=6.73,P<0.01];左室射血分数术前显著上升[(29.6±8.0)%比(23.1±5.3)%,q=6.49,P<0.01];6 min步行距离较术前明显延长[(382.0±12.8)m比(114.8±18.4)m,q=116.56,P<0.01]。术后6个月,42例获得随访患者心功能均恢复至NYHA分级Ⅰ~Ⅱ级。 结论: 初步研究结果显示,左心室辅助装置治疗终末期心力衰竭的效果较好,可作为移植前过渡治疗、永久性支持治疗或恢复前的过渡治疗方法。.

来源:Zhonghua Wai Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Cao X, Ding H, Wang JK, et al. [Application of left ventricular assist device in the treatment of end-stage heart failure:a multi-center report of 48 cases]. Zhonghua Wai Ke Za Zhi. 2025. PMID: 40147918. doi:10.3760/cma.j.cn112139-20241204-00548

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。